NORTH CHICAGO, Ill., Jan. 21, 2022 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a…Original Article
U.S. FDA Approves Second Indication for Skyrizi (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
